Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REM-JP02 Phase III Trial of Remimazolam Sedation for Gastrointestinal Endoscopy in Japan
jRCT2031220129Phase 3Completed
- Sponsor
- Mundipharma
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remimazolam, sponsored by Mundipharma. Primary endpoint: Success rate of sedation in gastrointestinal endoscopy. Started Jun 2022; status: completed.
02
Drugs
remimazolam
Beyond the preview
Go deeper on jRCT2031220129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220129.